An API for Genome Apps
By The Daily Scan,
The Daily Scan
| 09. 20. 2012
23andMe is opening up its application programming interface so that third-party developers can create apps that will piggyback on customers' personal genome data.
The company, which announced the API launch at last week's Quantified Self conference, says that genome apps should be of great interest to "self-tracker” community. Conference attendees "immediately latched onto the potential of the Personal Genome API for the self-tracking movement. Integrating various sets of genetic traits into sleep trackers, for example, was a popular topic."
Mike Polcari, director of engineering at 23andMe, tells Daily Scan sister publication BioInform that the company is taking privacy seriously. Interested developers will have to apply online in order to ensure that they are "real and identifiable "and that they "are being thoughtful about which pieces of the genome they are accessing," Polcari says.
In addition, individual-level data won't be personally identifiable to developers, and 23andMe customers will be able to decide whether they want their data accessible to an app.
Wired UK speculates that there may be a benefit for 23andMe benefactor Google, noting that "with the attitudes toward personal...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
